Physician profile
Joseph Scott
NPI 1043281710
$3,866.04
in general payments reported to CMS, 2019-2025
27 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.20 · 2020: $131 · 2021: $143 · 2022: $182 · 2023: $940 · 2024: $1,285 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $745.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $537.37 | 2022-2025 | Rexulti |
| Abbvie INC. | $371.91 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $366.24 | 2020-2025 | |
| Astellas Pharma US INC | $360.98 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $330.86 | 2023-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $280.98 | 2023-2025 | |
| Lilly USA, LLC | $168.26 | 2024-2025 | Jardiance, Kisunla, Mounjaro |
| Exact Sciences Corporation | $110.64 | 2024-2025 | Cologuard Collection Kit |
| Welch Allyn | $99.98 | 2020 | |
| Dexcom, INC. | $88.64 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $61.69 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.96 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $40.22 | 2024-2025 | Heplisav-B |
| Medtronic, INC. | $27.42 | 2025 | Intellis Adaptivestim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26.95 | 2021 | |
| Glaxosmithkline, LLC. | $26.72 | 2022-2023 | Shingrix, Arexvy |
| Genzyme Corporation | $25.69 | 2025 | |
| Inspire Medical Systems, INC. | $23.68 | 2023 | Inspire |
| Allergan, INC. | $18.85 | 2020 | |
| Esperion Therapeutics, INC. | $17.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2023 | Livalo |
| Phathom Pharmaceuticals, INC. | $15.09 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $14.13 | 2025 | Auvelity |
| Hologic Sales and Service, LLC | $13.33 | 2021 | |
| Horizon Therapeutics Plc | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.